EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Details
Age
Adult
Type of Study
Treatment
Locations
Highlands Ranch Hospital
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
Elena Shagisultanova, MD, PhD
Study ID
Protocol Number: 22-1554
More information available at ClinicalTrials.gov: NCT05514054
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers